MovDisordV3, Main, Exploration, bibRecord, 003A02

Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado–Joseph disease)

Identifieur interne : 003A02 ( Main/Exploration ); précédent : 003A01; suivant : 003A03

Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado–Joseph disease)

Auteurs : William Freeman [États-Unis] ; Zbigniew Wszolek [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2005-05.

RBID : ISTEX:D1FCB7ED2805393820D0B9047104E676305D289E

English descriptors

KwdEn :
- Adult, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (therapeutic use), Female, Humans, Injections, Intramuscular, Machado-Joseph Disease (complications), Machado-Joseph Disease (drug therapy), Machado-Joseph Disease (genetics), Muscle Spasticity (etiology), Muscle, Skeletal, Nerve Tissue Proteins (genetics), Neuromuscular Agents (administration & dosage), Neuromuscular Agents (therapeutic use), Nuclear Proteins, Point Mutation (genetics), Repressor Proteins.
MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , genetics : Nerve Tissue Proteins.
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- complications : Machado-Joseph Disease.
- drug therapy : Machado-Joseph Disease.
- etiology : Muscle Spasticity.
- genetics : Machado-Joseph Disease, Point Mutation.
- Adult, Female, Humans, Injections, Intramuscular, Muscle, Skeletal, Nuclear Proteins, Repressor Proteins.

Url:

https://api.istex.fr/document/D1FCB7ED2805393820D0B9047104E676305D289E/fulltext/pdf

DOI: 10.1002/mds.20442

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado–Joseph disease)</title>
<author><name sortKey="Freeman, William" sort="Freeman, William" uniqKey="Freeman W" first="William" last="Freeman">William Freeman</name>
</author>
<author><name sortKey="Wszolek, Zbigniew" sort="Wszolek, Zbigniew" uniqKey="Wszolek Z" first="Zbigniew" last="Wszolek">Zbigniew Wszolek</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D1FCB7ED2805393820D0B9047104E676305D289E</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20442</idno>
<idno type="url">https://api.istex.fr/document/D1FCB7ED2805393820D0B9047104E676305D289E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003F67</idno>
<idno type="wicri:Area/Istex/Curation">003F67</idno>
<idno type="wicri:Area/Istex/Checkpoint">002412</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Freeman W:botulinum:toxin:type</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15747361</idno>
<idno type="wicri:Area/PubMed/Corpus">003114</idno>
<idno type="wicri:Area/PubMed/Curation">003114</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003215</idno>
<idno type="wicri:Area/Ncbi/Merge">001187</idno>
<idno type="wicri:Area/Ncbi/Curation">001187</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001187</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Freeman W:botulinum:toxin:type</idno>
<idno type="wicri:Area/Main/Merge">005089</idno>
<idno type="wicri:Area/Main/Curation">003A02</idno>
<idno type="wicri:Area/Main/Exploration">003A02</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado–Joseph disease)</title>
<author><name sortKey="Freeman, William" sort="Freeman, William" uniqKey="Freeman W" first="William" last="Freeman">William Freeman</name>
<affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Mayo Clinic, Jacksonville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Wszolek, Zbigniew" sort="Wszolek, Zbigniew" uniqKey="Wszolek Z" first="Zbigniew" last="Wszolek">Zbigniew Wszolek</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Mayo Clinic, Jacksonville</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-05">2005-05</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="644">644</biblScope>
<biblScope unit="page" to="644">644</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D1FCB7ED2805393820D0B9047104E676305D289E</idno>
<idno type="DOI">10.1002/mds.20442</idno>
<idno type="ArticleID">MDS20442</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Botulinum Toxins, Type A (administration & dosage)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intramuscular</term>
<term>Machado-Joseph Disease (complications)</term>
<term>Machado-Joseph Disease (drug therapy)</term>
<term>Machado-Joseph Disease (genetics)</term>
<term>Muscle Spasticity (etiology)</term>
<term>Muscle, Skeletal</term>
<term>Nerve Tissue Proteins (genetics)</term>
<term>Neuromuscular Agents (administration & dosage)</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Nuclear Proteins</term>
<term>Point Mutation (genetics)</term>
<term>Repressor Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Nerve Tissue Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Machado-Joseph Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Machado-Joseph Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Muscle Spasticity</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Machado-Joseph Disease</term>
<term>Point Mutation</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intramuscular</term>
<term>Muscle, Skeletal</term>
<term>Nuclear Proteins</term>
<term>Repressor Proteins</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
</region>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Freeman, William" sort="Freeman, William" uniqKey="Freeman W" first="William" last="Freeman">William Freeman</name>
</noRegion>
<name sortKey="Freeman, William" sort="Freeman, William" uniqKey="Freeman W" first="William" last="Freeman">William Freeman</name>
<name sortKey="Wszolek, Zbigniew" sort="Wszolek, Zbigniew" uniqKey="Wszolek Z" first="Zbigniew" last="Wszolek">Zbigniew Wszolek</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A02 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A02 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:D1FCB7ED2805393820D0B9047104E676305D289E
   |texte=   Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado–Joseph disease)
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado–Joseph disease)

Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado–Joseph disease)

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.